RCM
NVCR icon

Raleigh Capital Management’s NovoCure NVCR Stock Holding History

Raleigh Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-26
Closed -$445 – 1040
2024
Q2 		$445 Hold
26
– – ﹤0.01% 912
2024
Q1 		$406 Hold
26
– – ﹤0.01% 900
2023
Q4 		$388 Hold
26
– – ﹤0.01% 1006
2023
Q3 		$420 Hold
26
– – ﹤0.01% 890
2023
Q2 		$1.08K Buy
+26
New +$1.61K ﹤0.01% 761

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Raleigh Capital Management's NVCR Position: Q3 2024 in Review

Raleigh Capital Management sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 26 shares — an estimated $445 sold.

Raleigh Capital Management first reported a position in NVCR in Q2 2023 and held it in 5 quarters. The position peaked at $1.08K in Q2 2023. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Raleigh Capital Management reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 26 NovoCure shares in Q3 2024, an estimated $445.
  • Raleigh Capital Management first reported a position in NovoCure in Q2 2023 and held it in 5 quarters.
  • Raleigh Capital Management's NovoCure position peaked at $1.08K in Q2 2023.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Raleigh Capital Management's 13F filing for Q3 2024, filed 21 Oct 2024.